PALO
ALTO, Calif., Oct. 11,
2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused
on the development of innovative therapies for hepatitis delta
virus (HDV) and other serious diseases, today announced that
David Cory, President and CEO, will
present a company overview at the H.C. Wainwright Third Annual
Hepatitis B Virus (HBV) Virtual Conference on Tuesday, October 18, 2022 at 3:00 PM ET. The company will also host one-on-one
meetings with investors at the conference.
A live webcast of the presentation will be available on the
Investors section of the Eiger BioPharmaceuticals website at
www.eigerbio.com, and a replay will be available on the website for
at least 90 days.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies for hepatitis delta virus
(HDV) and other serious diseases. The Eiger HDV platform includes
two first-in-class therapies in Phase 3 that target critical host
processes involved in viral replication. All five Eiger rare
disease programs have been granted FDA Breakthrough Therapy
designation: lonafarnib/ritonavir for HDV, peginterferon lambda for
HDV, avexitide for congenital hyperinsulinism, avexitide for
post-bariatric hypoglycemia, and Zokinvy® (lonafarnib)
for progeria.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-hc-wainwright-third-annual-hepatitis-b-virus-hbv-virtual-conference-301645595.html
SOURCE Eiger BioPharmaceuticals, Inc.